The Zhitong Finance App learned that Citi released a research report saying that in response to the impact of anti-corruption policies on drug sales and the continued expansion of the VBP scope, Sinopharm Holdings (01099.HK) revenue forecasts for 2026 to 2028 were lowered by 1% each, and the net profit forecast for 2026 to 2028 was lowered by 6%, 7%, and 8%, respectively, in response to greater pressure on gross margin compared with expectations. The target price was lowered from HK$22.6 to HK$20.4, which is equivalent to 1.0 times the projected price-earnings growth rate (PEG) in 2027. The current price of the stock is equivalent to 5.6 times the predicted price-earnings ratio in 2027, with a dividend rate of about 5%. The valuation is at an all-time low. The dividend ratio is attractive, and it maintains a “buy” rating.

The Zhitong Finance App learned that Citi released a research report saying that in response to the impact of anti-corruption policies on drug sales and the continued expansion of the VBP scope, Sinopharm Holdings (01099.HK) revenue forecasts for 2026 to 2028 were lowered by 1% each, and the net profit forecast for 2026 to 2028 was lowered by 6%, 7%, and 8%, respectively, in response to greater pressure on gross margin compared with expectations. The target price was lowered from HK$22.6 to HK$20.4, which is equivalent to 1.0 times the projected price-earnings growth rate (PEG) in 2027. The current price of the stock is equivalent to 5.6 times the predicted price-earnings ratio in 2027, with a dividend rate of about 5%. The valuation is at an all-time low. The dividend ratio is attractive, and it maintains a “buy” rating.